Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib Meeting Abstract


Authors: Diamond, E. L.; Rosenblum, M.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V. M.; Hatzoglou, V.; Young, R.; Ulaner, G. A.; Reddy, R.; Abdel-Wahab, O.; Durham, B. H.
Abstract Title: Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib
Meeting Title: 38th Annual Meeting of the Histiocyte Society
Journal Title: Pediatric Blood and Cancer
Volume: 70
Issue: Suppl. 1
Meeting Dates: 2022 Sep 18-20
Meeting Location: Stockholm, Sweden
ISSN: 1545-5009
Publisher: Wiley Periodicals, Inc  
Date Published: 2023-02-01
Start Page: S10
Language: English
ACCESSION: WOS:000904088900021
PROVIDER: wos
DOI: 10.1002/pbc.30097
Notes: Meeting Abstract -- Meeting also held virtually -- Electronic article number: e30097 -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Mario E Lacouture
    413 Lacouture
  2. Robert J Young
    186 Young
  3. Jasmine Helen Francis
    200 Francis
  4. Marc Rosenblum
    393 Rosenblum
  5. Raajit Kumar Rampal
    246 Rampal
  6. Eli Louis Diamond
    155 Diamond
  7. Benjamin Heath Durham
    98 Durham
  8. Mariko   Yabe
    35 Yabe
  9. Ryan Padira Reddy
    9 Reddy
Related MSK Work